Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;16(12):2421-2428.
doi: 10.1111/cts.13655. Epub 2023 Oct 11.

Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

Paloma Moraga  1 , Paula Prieto  1 , Almari Conradie  2 , Majda Benhayoun  2 , Vicki Rousell  3 , Maria Davy  3 , Uwe Fuhr  4 , Rosa Antonijoan Arbos  5   6   7 , Francisco Abad-Santos  8   9 , Antonio Portolés  10   11 , Jolanda Van Duinen  12 , Antonio J Carcas  1   13   14 , Alberto M Borobia  1   13   14 ; ERA4TB Consortium
Affiliations

Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

Paloma Moraga et al. Clin Transl Sci. 2023 Dec.

Abstract

First-time-in-human (FTIH) trials are designed to generate information on the safety, tolerability, as well as the pharmacokinetic and pharmacodynamics profile of new drugs. To ensure the safety of participants, these trials need to be conducted at specifically equipped phase I clinical trial units (CTUs). In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the European Union (EU) regulatory guidelines, one of the aims of the European Regime Accelerator for Tuberculosis (ERA4TB) project is to collaboratively create a feasibility tool, through a partnership between public and private entities, for the validation of CTUs selected to conduct FTIH trials. A feasibility form, encompassing nine sections, was created to gather information on the unit in relation to key attributes of FTIH trials. Collaboratively, industry and academic partners defined the minimal criteria to ensure the adherence of CTUs to the principles of ICH GCP and regulations outlined by the European Medicines Agency (EMA) for the execution of FTIH trials. Subsequently, all CTUs available for the project were assessed for FTIH trial eligibility. The introduction of the certification procedure through the feasibility tool within ERA4TB resulted in the accreditation of the five academic CTUs, which are now prepared to carry out FTIH trials as part of the Consortium. The developed feasibility tool aims to establish open and widely used minimum requirements for the validation of academic CTUs as FTIH units, marking it as the inaugural tool for CTU validation resulting from the collaboration between industry and academia within the ERA4TB project. The established partnership has enabled an innovative and novel way of working.

PubMed Disclaimer

Conflict of interest statement

The authors declared no competing interests for this work.

Figures

FIGURE 1
FIGURE 1
Schematic map of the early phase I trials registered on clinicaltrials.gov. (adapted from clinicaltrials.gov).
See this image and copyright information in PMC

References

    1. Novartis España . Desarrollo de fármacos. https://www.novartis.com/es‐es/investigacion‐y‐desarrollo/desarrollo‐de‐.... Accessed May 4, 2023.
    1. Biobide . The drug discovery process: what is it and its major steps. https://blog.biobide.com/the‐drug‐discovery‐process#:~:text=in%20the%20a.... Accessed May 4, 2023.
    1. Graef KM, Okoye I, Ohene Oti NO, Dent J, Odedina FT. Operational strategies for clinical trials in Africa. JCO Glob Oncol. 2020;6:973‐982. - PMC - PubMed
    1. Maragall FP. ¿Cuáles son las fases de un Ensayo Clínico? Hablemos del Alzheimer. https://blog.fpmaragall.org/fases‐ensayo‐clinico. Accessed May 4, 2023.
    1. Mishra A, Sarangi SC, Reeta K. First‐in‐human dose: current status review for better future perspectives. Eur J Clin Pharmacol. 2020;76(9):1237‐1243. - PubMed

Publication types